PE/Cyanine7 anti-mouse CD3ε Antibody

Pricing & Availability
Clone
145-2C11 (See other available formats)
Regulatory Status
RUO
Other Names
CD3ε, T3, CD3
Isotype
Armenian Hamster IgG
Ave. Rating
Submit a Review
Product Citations
publications
145-2C11_PECy7_020608
C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE/Cyanine7 (filled histogram) or Armenian hamster IgG PE/Cyanine7 isotype control (open histogram).
  • 145-2C11_PECy7_020608
    C57BL/6 mouse splenocytes were stained with CD3e (clone 145-2C11) PE/Cyanine7 (filled histogram) or Armenian hamster IgG PE/Cyanine7 isotype control (open histogram).
Compare all formats See PE/Cyanine7 spectral data
Cat # Size Price Quantity Check Availability Save
100319 25 µg 71€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100320 100 µg 159€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD3ε is a 20 kD transmembrane protein, also known as CD3 or T3. It is a member of the Ig superfamily and primarily expressed on T cells, NK-T cells, and at different levels on thymocytes during T cell differentiation. CD3ε forms a TCR complex by associating with the CD3δ, γ and ζ chains, as well as the TCR α/β or γ/δ chains. CD3 plays a critical role in TCR signal transduction, T cell activation, and antigen recognition by binding the peptide/MHC antigen complex.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Armenian Hamster
Immunogen
H-2Kb-specific mouse cytotoxic T lymphocyte clone BM10-37
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE/Cyanine7 under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Clone 145-2C11 is useful for in vitro blocking of target-specific CTL-mediated cell lysis1, as well as T cell activation assays, inducing proliferation and cytokine production1,2,7,12,16. It also induces apoptosis in immature thymocytes32,  and in vivo T cell depletion8-10. Additional reported applications (for relevant formats of this clone) include: immunoprecipitation1, immunohistochemical staining14,15 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, Western blotting4, complement-mediated cytotoxicity6, in vitro and in vivo stimulation of T cells1,2,7,12,16, immunofluorescent staining5, and in vivo T cell depletion8-10. The 145-2C11 antibody has been reported to block the binding of 17A2 antibody to CD3 epsilon-specific T cells11. Clone 145-2C11 is not recommended for formalin-fixed paraffin embedded sections. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 100314). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100340) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Additional Product Notes
BioLegend is in the process of converting the name PE/Cy7 to PE/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our PE/Cyanine7 products. Please contact Technical Service if you have any questions.
Application References
  1. Leo O, et al. 1987. P. Natl. Acad. Sci. USA 84:1374. (IP, Activ, Block)
  2. Kruisbeek AM, et al. 1991. In Current Protocols in Immunology. 3.12.1. (Activ)
  3. Duke RC, et al. 1995. Current Protocols in Immunology. 3.17.1.
  4. Salvadori S, et al. 1994. J. Immunol. 153:5176. (WB)
  5. Payer E, et al. 1991. J. Immunol. 146:2536. (IF)
  6. Jacobs H, et al. 1994. Eur. J. Immunol. 24:934. (CMCD)
  7. Vossen ACTM, et al. 1995. Eur. J. Immunol. 25:1492. (Activ)
  8. Henrickson M, et al. 1995. Transplantation 60:828. (Deplete)
  9. Kinnaert P, et al. 1996. Transpl. Int. 9:386. (Deplete)
  10. Han WR, et al. 1999. Transpl. Immunol. 7:207. (Deplete)
  11. Miescher GC, et al. 1989. Immunol. Lett. 23:113. (Block)
  12. Terrazas LI, et al. 2005. Intl. J. Parasitology. 35:1349. (Activ)
  13. Ko SY, et al. 2005. J. Immunol. 175:3309.
  14. Podd BS, et al. 2006. J. Immunol. 176:6532. (IHC-F)
  15. Tilley SL, et al. 2007. J. Immunol. 178:3208. (IHC-F)
  16. Wang W, et al. 2007. J. Immunol. 178:4885. (Activ)
  17. Xiao S, et al. 2007. J. Exp. Med. 204:1691.
  18. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245. (FC) PubMed.
  19. Curtsinger JM, et al.2005. J. Immunol. 175:4392. PubMed
  20. Guo Y, et al. 2008. Blood 112:480. PubMed
  21. Kenna TJ, et al. 2008. Blood 111:2091.
  22. Perchonock CE, et al. 2007. J. Immunol. 179:1768. PubMed
  23. Perchonock GE, et al. 2006. Mol. Cell. Biol. 26:6005. PubMed
  24. Kanaya T, et al. 2008. Am. J. Physiol. Gastrointest. Liver Physiol. 295:G273. PubMed
  25. de Koning BA, et al. 2006. Int. Immunol. 18:941. PubMed
  26. Schulteis RD, et al. 2008. Blood 295:G273. PubMed
  27. Qi Q, et al. 2009. Blood 114:564. PubMed
  28. Helmersson S, et al. 2013. Am J Pathol. 9440:123. Pubmed
  29. Wu S, et al. 2014. Clin Vaccine Immunol. 21:156. PubMed
  30. Yan J, et al. 2014. Vaccine. 32:2833. PubMed
  31. Guiterrez DA, et al. 2014. Diaebetes. 63:3827. PubMed
  32. Shi YF, et al. 1991. J Immunol. 146:3340. (Apop)
Product Citations
  1. Huang Y, et al. 2015. Proc Natl Acad Sci U S A. 112:39. PubMed
  2. Cabañero D, et al. 2020. Elife. 9:00. PubMed
  3. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  4. Strickley JD, et al. 2019. Nature. 575:519. PubMed
  5. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  6. Aguilar EG, et al. 2021. Blood Adv. 5:4219. PubMed
  7. Oetjen LK et al. 2017. Cell. 171(1):217-228 . PubMed
  8. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  9. Tatsuguchi T, et al. 2022. Int Immunol. 34:277. PubMed
  10. Zhu H, et al. 2018. Elife. 7:. PubMed
  11. Buxadé M, et al. 2018. J Exp Med. 215:2901. PubMed
  12. Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  13. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  14. Li ZX, et al. 2022. Arch Virol. :. PubMed
  15. Huai W, et al. 2019. J Exp Med. 216:772. PubMed
  16. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  17. Schulthess J et al. 2019. Immunity. 50(2):432-445 . PubMed
  18. Gopinathan G, et al. 2022. Mol Cancer Ther. 21:1030. PubMed
  19. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  20. Zhao B, et al. 2021. Cell Reports. 36(3):109401. PubMed
  21. Bartleson JM, et al. 2020. Nat Immunol. 1384:21. PubMed
  22. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  23. Yang W, et al. 2020. Mucosal Immunol. 13:788. PubMed
  24. Li Z, et al. 2022. Elife. 11:. PubMed
  25. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  26. Tuttle KD, et al. 2020. Cell Rep. 33:108407. PubMed
  27. Xiao Y, et al. 2021. Cancer Cell. 39(3):423-437.e7. PubMed
  28. Emgård J, et al. 2018. Immunity. 143:419. PubMed
  29. Alexander RK, et al. 2020. eLife. 9:e54090.. PubMed
  30. Chun E, et al. 2020. Immunity. 51(5):871-884.e6.. PubMed
  31. Deng Z, et al. 2017. Oncogene. 36:639. PubMed
  32. Westfall S, et al. 2020. Brain Behav Immun. . PubMed
  33. He Y, et al. 2021. Cell Metabolism. 33(5):988-1000.e7. PubMed
  34. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  35. Wu Y, et al. 2021. Nat Commun. 12:2346. PubMed
  36. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  37. Synn CB, et al. 2022. Clin Transl Immunology. 11:e1364. PubMed
  38. Tacconi C, et al. 2021. Cell Reports. 35(2):108993. PubMed
  39. Lu M, et al. 2021. J Virol. 95:e0059221. PubMed
  40. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  41. Tran NT, et al. 2020. STAR Protocols. 1(1):100028. PubMed
  42. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  43. Williams JW, et al. 2017. Circ Res. 121:662. PubMed
  44. Kubota S, et al. 2019. Nat Commun. 10:1653. PubMed
  45. Wu S, et al. 2022. BMC Immunol. 23:17. PubMed
  46. Wang R, et al. 2022. Front Immunol. 13:947756. PubMed
  47. De Ponte Conti B, et al. 2021. Elife. 10:. PubMed
  48. Peng L, et al. 2022. Cell Rep Med. 3:100634. PubMed
  49. Li J, et al. 2013. Arch Immunol Ther Exp (Warsz). 61:237. PubMed
  50. Huang Y, et al. 2016. J Immunol. 196: 217 - 231. PubMed
  51. Uematsu T, et al. 2016. Sci Rep. 6:37815. PubMed
  52. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  53. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  54. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  55. Riva A, et al. 2017. PLoS One.. 10.1371/journal.pone.0181964. PubMed
  56. Yasuma K, et al. 2016. PLoS Pathog. 12: 1005372. PubMed
  57. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  58. Damgaard RB et al. 2016. Cell. 166(5):1215-1230 . PubMed
  59. Zhao N, et al. 2018. J Clin Invest. 26:84. PubMed
  60. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  61. Takahashi T, et al. 2017. J Exp Med. 10.1084/jem.20160247. PubMed
  62. Halim TYF et al. 2018. Immunity. 48(6):1195-1207 . PubMed
  63. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  64. Ireland L, et al. 2020. Front Immunol. 11:297. PubMed
  65. Hong JP, et al. 2020. Cell Reports Medicine. 1(3):100035. PubMed
  66. Qi Q, et al. 2009. Blood. 114:564. PubMed
  67. Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed
  68. Fitzpatrick Z, et al. 2020. Nature. 587:472. PubMed
  69. Chen J, et al. 2014. Cell Res. 24:1050. PubMed
  70. Walker JA, et al. 2020. Immunity. 51(1):104-118. PubMed
  71. White JP et al. 2018. Cell. 175(5):1198-1212 . PubMed
  72. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  73. Celorrio M, et al. 2022. Acta Neuropathol Commun. 10:10. PubMed
  74. Fite BZ, et al. 2021. Sci Rep. 11:927. PubMed
  75. Wang Y, et al. 2020. Immunity. 53(6):1168-1181.e7. PubMed
  76. Goc J, et al. 2021. Cell. :. PubMed
  77. Li Z et al. 2018. Immunity. 49(4):640-653 . PubMed
  78. Ioanna E Galani et al. 2017. Immunity. 46(5):875-890 . PubMed
  79. Nabekura T, et al. 2020. Immunity. 96:52. PubMed
  80. Uematsu T, et al. 2015. Sci Rep. 5: 17577. PubMed
RRID
AB_312684 (BioLegend Cat. No. 100319)
AB_312685 (BioLegend Cat. No. 100320)

Antigen Details

Structure
Ig superfamily, forms CD3/TCR complex with CD3δ, γ and ζ subunits and TCR (α/β and γ/δ), 20 kD
Distribution

Thymocytes (differentiation dependent), mature T cells, NK-T cells

Function
TCR signal transduction, T cell activation, antigen recognition
Ligand/Receptor
Peptide antigen/MHC-complex
Cell Type
NKT cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules, TCRs
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Davis MM. 1990. Annu. Rev. Biochem. 59:475.
3. Weiss A, et al. 1994. Cell 76:263.

Gene ID
12501 View all products for this Gene ID
UniProt
View information about CD3epsilon on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • APC anti-mouse CD3ε

  • Biotin anti-mouse CD3ε

  • FITC anti-mouse CD3ε

  • PE anti-mouse CD3ε

  • PE/Cyanine5 anti-mouse CD3ε

  • Purified anti-mouse CD3ε

  • PE/Cyanine7 anti-mouse CD3ε

  • Alexa Fluor® 488 anti-mouse CD3ε

  • Alexa Fluor® 647 anti-mouse CD3ε

  • PerCP anti-mouse CD3ε

  • PerCP/Cyanine5.5 anti-mouse CD3ε

  • Purified anti-mouse CD3ε (Maxpar® Ready)

  • APC/Cyanine7 anti-mouse CD3ε

  • Pacific Blue™ anti-mouse CD3ε

  • Brilliant Violet 421™ anti-mouse CD3ε

  • Ultra-LEAF™ Purified anti-mouse CD3ε

  • PE/Dazzle™ 594 anti-mouse CD3ε

  • Brilliant Violet 510™ anti-mouse CD3ε

  • Brilliant Violet 605™ anti-mouse CD3ε

  • Brilliant Violet 711™ anti-mouse CD3ε

  • Brilliant Violet 785™ anti-mouse CD3ε

  • APC/Fire™ 750 anti-mouse CD3ε

  • GoInVivo™ Purified anti-mouse CD3ε

  • Spark YG™ 593 anti-mouse CD3

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account